Zobrazeno 1 - 10
of 280
pro vyhledávání: ''
Autor:
Chuan Zheng, Ding-Kun Zhang, Fang Wang, Yunzhen Shi, Xi-Chuan Wei, Ruifang Yuan, Jinming Zhang, Chuanhong Luo, Ming Yang, Qi Hu, Yi Wu, Jinhui Yang
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Background:Zanthoxylum schinifolium is a common herbal medicine in Southwest China. It is also a condiment commonly used in many families. In Chinese folk medicine, Z. schinifolium is considered to have the effect of relieving migraine, but there is
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Si-Miao-Yong-An decoction (SMYAD), a traditional Chinese medicine formula, is mainly used to clear away heat and detoxify and to promote blood circulation and relieve pain. Diabetic retinopathy (DR) is the most common type of microvascular complicati
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Phenotype screening has become an important tool for the discovery of active components in traditional Chinese medicine. Anshen Buxin Six Pills (ASBX) are a traditional Mongolian medicine used for the treatment of neurosis in clinical settings. Howev
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Aims: We aim to perform a systematic review and meta-analysis examining randomized controlled trials assessing the efficacy and safety of sacubitril/valsartan in patients on renal outcomes, in comparison with the renin–angiotensin–aldosterone sys
Autor:
Sang Soo Lee, Govindasamy Agoramoorthy, Manojit Bhattacharya, Ashish Ranjan Sharma, Chiranjib Chakraborty
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
SARS-CoV-2 has spread across the globe in no time. In the beginning, people suffered due to the absence of efficacious drugs required to treat severely ill patients. Nevertheless, still, there are no established therapeutic molecules against the SARS
Autor:
Lucia Gozzo, Calogero Vetro, Serena Brancati, Laura Longo, Daniela Cristina Vitale, Giovanni Luca Romano, Elisa Mauro, Paolo Fabio Fiumara, Cinzia Maugeri, Marina Silvia Parisi, Ilaria Dulcamare, Bruno Garibaldi, Andrea Duminuco, Giuseppe Alberto Palumbo, Francesco Di Raimondo, Filippo Drago
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
The potent oral inhibitor of BCL2, venetoclax (VEN), used to treat adults with chronic lymphocytic leukaemia, has been approved in US for the treatment of naïve patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy and recently
Autor:
Muhan Jing, Shanshan Wang, Ding Li, Zeyu Wang, Ziwen Li, Yichen Lu, Tong Sun, Chen Qiu, Fang Chen, Haijuan Yu, Wei Zhang
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Lorcaserin is a serotonergic agonist specific to the 5-hydroxytryptamine 2c receptor (5-HT2CR) that is FDA approved for the long-term management of obesity with or without at least one weight-related comorbidity. Lorcaserin can restrain patients’ a
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with chemotherapy as a first-line therapy for advanced nonsquamous non–small-cell lung cancer (NSCLC) in China. The purpose of this study was to determine whether u
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Background: Although the predominant airway inflammation in chronic obstructive pulmonary disease (COPD) is neutrophilic, approximately 20–40% of COPD patients present with eosinophilic airway inflammation. Compared with non-eosinophilic COPD patie
Autor:
Hiroyuki Takahashi, Daiji Kawanami, Makito Tanabe, Yoshimi Muta, Dai Nagata, Naoki Oda, Yuichi Takashi
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Diabetic kidney disease (DKD) is a major cause of end-stage kidney disease (ESKD) worldwide. Mineralocorticoid receptor (MR) plays an important role in the development of DKD. A series of preclinical studies revealed that MR is overactivated under di